Dr. Maria Castro invited to speak at 2025 Spring Interdisciplinary Seminar Series
Title: “Reprogramming of Myelopoiesis in Mutant IDH 1 Gliomas Enhances the Response to Immune-Mediated Therapies”
Title: “Reprogramming of Myelopoiesis in Mutant IDH 1 Gliomas Enhances the Response to Immune-Mediated Therapies”
Dr. Maria Castro will be presenting as a Keynote speaker at 2025 Center for Cancer Metabolism Symposium in Columbus, Ohio April 14-15.
Title: “Glioma Immune Microenvironment: Mechanisms Impacting Clinical Outcomes of Immunotherapies” WOCAP is a campus-wide faculty network at UM that supports scholarship focused on understanding the experiences of women of color in the academy.
Unifying Cancer Science and Medicine: A Continuum of Innovation for Impact The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting showcases…
Title: “Epigenetic Reprogramming of the Immune Microenvironment in Gliomas: Impact on the Efficacy of Immunotherapies” More Information Here
Dr. Maria Castro will be presenting at UCSF Helen Diller Family Comprehensive Cancer Center Friday Seminar.
This is the sixth conference in the biennial Cell Signalling and its Therapeutic Implications (CSTI) series in Mornington Peninsula which brings together researchers, students and clinicians to accelerate our understanding of cell signalling and how discoveries in this area can improve the diagnosis, prognosis and treatment of cancer. The meeting also involves presentation of the Lackmann Award for Translational Research in honour of the late…
Dr. Maria Castro will be speaking on Reprogramming of the immune microenvironment in gliomas impact on therapeutics.
Dr. Maria Castro will be speaking on “Epigenetic Reprogramming of the Immune Microenvironment in Gliomas, Impact on Immunotherapies”